Methods for modifying human antibodies by glycan engineering

Patent metadata

Field	Value
Publication number	US-10087236-B2
Application number	US-95935110-A
Country	US
Kind code	B2
Filing date	Dec 2, 2010
Priority date	Dec 2, 2009
Publication date	Oct 2, 2018
Grant date	Oct 2, 2018

Abstract

Modified Fc regions of antibodies and antibody fragments, both human and humanized, and having enhanced stability and efficacy, are provided. Fc regions with core fucose residues removed, and attached to oligosaccharides comprising terminal sialyl residues, are provided. Antibodies comprising homogeneous glycosylation of Fc regions with specific oligosaccharides are provided. Fc regions conjugated with homogeneous glycoforms of monosaccharides and trisaccharides, are provided. Methods of preparing human antibodies with modified Fc using glycan engineering, are provided.

First claim

What is claimed is:

1. A method for glycan engineering the Fc region of a human, chimeric or humanized IgG1 or IgG3 glycosylated antibody, the method comprising the steps of:
(a) providing a human, chimeric or humanized IgG1 or IgG3 glycosylated antibody comprising an oligosaccharide attached at each Asn 297 in the Fc region;
(b) contacting the human, chimeric or humanized IgG1 or IgG3 glycosylated antibody with an endo-β-N-acetylglucosaminidase (endo-NAG) and alpha-fucosidase thereby digesting the oligosaccharide to a defucosylated N-Acetylglucosamine (GlcNAc) unit attached at each Asn 297 in the Fc region;
(c) contacting the defucosylated N-Acetylglucosamine (GlcNAc) unit with an endo-β-N-acetylglucosaminidase (endo-NAG) and a synthetic Gal 2 GlcNAc 2 Man 3 GlcNAc moiety joined to a leaving group, thereby coupling the terminal GlcNac of the synthetic Gal 2 GlcNAc 2 Man 3 GlcNAc moiety to the defucosylated N-Acetylglucosamine (GlcNAc) unit to form the structure Gal 2 GlcNAc 2 Man 3 GlcNAc 2 attached at each Asn 297 of the Fc region of the human, chimeric or humanized IgG1 or IgG3 glycosylated antibody; and
(d) contacting the attached Gal 2 GlcNAc 2 Man 3 GlcNAc 2 of step (c) with an alpha-2,6-sialyltransferase, CMP-Neu5Ac and a set of CMP-Neu5Ac regeneration enzymes comprising a pyrophosphatase and a cytidine monophosphate kinase, thereby adding a terminal Neu5Ac to each terminal galactose of the attached Gal 2 GlcNAc 2 Man 3 GlcNAc 2 , wherein the glycan engineered human, chimeric or humanized IgG1 or IgG3 antibody has a Neu5Ac 2 Gal 2 GlcNAc 2 Man 3 GlcNAc 2 attached at each Asn 297 in the Fc region, and wherein the CMP-Neu5Ac is regenerated following the addition of the terminal Neu5Ac.

2. The method of claim 1 , wherein the leaving group is selected from the group consisting of: fluoride (F), OH (hydroxy), and oxazoline.

3. The method of claim 1 , wherein the endo-β-N-acetylglucosaminidase (endo-NAG) in step (b) is selected from the group consisting of: Endo H, Endo A, Endo M, Endo F2, and Endo F3.

4. The method of claim 3 , wherein the endo-β-N-acetylglucosaminidase (endo-NAG) used in step (b) is Endo H.

5. A method for glycan engineering the Fc region-of a human, chimeric or humanized IgG1 or IgG3 glycosylated antibody, the method comprising the steps of:
(a) providing a human, chimeric or humanized IgG1 or IgG3 glycosylated antibody comprising an oligosaccharide attached at each Asn 297in the Fc region; and
(b) contacting the human, chimeric or humanized IgG1 or IgG3 glycosylated antibody with an endo-β-N-acetylglucosaminidase (endo-NAG) and alpha-fucosidase thereby digesting the oligosaccharide to a defucosylated N-Acetylglucosamine (GlcNAc) unit attached at each Asn 297 in the Fc region; and;
(c) contacting the defucosylated N-Acetylglucosamine (GlcNAc) unit with an endo-β-N-acetylglucosaminidase (endo-NAG) and a synthetic Neu5Ac 2 Gal 2 GlcNAc 2 Man 3 GlcNAc moiety joined to a leaving group, thereby coupling the terminal GlcNac of the synthetic moiety to the defucosylated N-Acetylglucosamine (GlcNAc) unit to form the structure Neu5Ac 2 Gal 2 G1cNAc 2 Man 3 G1cNAc 2 attached at each Asn 297 of the Fc region of the human, chimeric or humanized IgG1 or IgG3 glycosylated antibody.

6. The method of claim 5 , wherein the leaving group is selected from the group consisting of: fluoride (F), OH (hydroxy), and oxazoline.

7. The method of claim 5 , wherein the endo-β-N-acetylglucosaminidase (endo-NAG) in step (b) is selected from the group consisting of: Endo H, Endo A, Endo M, Endo F2, and Endo F3.

8. The method of claim 7 , wherein the endo-β-N-acetylglucosaminidase (endo-NAG) used in step (b) is Endo H.

Assignees

• Wong Chi Huey
• Wu Chung Yi
• Academia Sinica

Inventors

• Wong Chi-Huey
• Wu Chung-Yi

Classifications

• C12P21/005

  Glycopeptides, glycoproteins · CPC title

• C07K2317/10

  characterized by their source of isolation or production · CPC title

• C12Y302/01051

  Alpha-L-fucosidase (3.2.1.51) · CPC title

• C12Y204/99

  transferring other glycosyl groups (2.4.99) · CPC title

• C07K2317/21

  from primates, e.g. man · CPC title